March 14th 2024
Although research on cannabinoids is now allowed in a growing number of countries, there are still a number of restrictions and corresponding licenses and permits required to work with these chemicals.
FDA to Evaluate BeiGene’s Tevimbra Combination for Gastric/Gastroesophageal Junction Adenocarcinoma
February 27th 2024Trial data support Tevimbra combined with chemotherapy as a potential first-line treatment option for patients with locally advanced, unresectable or metastatic gastric or gastroesophageal junction cancer.
Bayer Granted FDA Breakthrough Therapy Designation for Non-Small Cell Lung Cancer Drug
February 26th 2024BAY 2927088 is an oral, reversible small molecule tyrosine kinase inhibitor being analyzed for the treatment of unresectable or metastatic non-small cell lung cancer with tumors that have activating HER2 mutations.
FDA Grants Priority Review to Dupixent for Uncontrolled Chronic Obstructive Pulmonary Disease
February 23rd 2024The FDA has assigned a supplemental Biologics License Application submitted by Regeneron and Sanofi for Dupixent in the treatment of COPD with type 2 inflammation with a PDUFA date of June 27, 2024.
FDA to Evaluate BLA for Datopotamab Deruxtecan in Non-Small Cell Lung Cancer
February 20th 2024The FDA set a Prescription Drug User Fee Act date during Q4 of 2024 for the biologics license application for datopotamab deruxtecan in patients with previously treated advanced nonsquamous non-small cell lung cancer.